Cancer risk in the EMPA-REG OUTCOME trial. Reply to Shaikh AMY [letter] and Kohler S, Lee J, George JT et al [letter]

Huilin Tang, Jiali Han, Yiqing Song

Research output: Contribution to journalLetter

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)2538-2539
Number of pages2
JournalDiabetologia
Volume60
Issue number12
DOIs
StatePublished - Dec 1 2017

Keywords

  • Bladder cancer
  • Empagliflozin
  • SGLT2 inhibitors

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this